Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Neoadjuvant Chemoradiotherapy Followed by Immunotherapy vs Neoadjuvant Chemoimmunotherapy in ESCC
NCT06509568Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Started Aug 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06509568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509568.